A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
A phase 2 trial of Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Lantern Pharma Inc., now recruiting.
Overview
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma is a phase 2 interventional study registered as NCT05456256 by Lantern Pharma Inc., with 90 participants planned, started 2023-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: LP-300, Pemetrexed and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.